Matthew Murphy | Manager, IR |
Christopher Posner | President, CEO & Director |
Ryan Maynard | CFO |
Scott Terrillion | Chief Compliance Officer, General Counsel & Corporate Secretary |
Dennis Ding | Jefferies |
Annabel Samimy | Stifel, Nicolaus & Company |
Joseph Stringer | Needham & Company |
Sumant Kulkarni | Canaccord Genuity |
David Amsellem | Piper Sandler & Co. |
Chi Fong | Bank of America Merrill Lynch |
Thank you for standing by, and welcome to Cara Therapeutics' Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you I would now like to hand the call over to Matt Murphy, Investor Relations.